Pasar al contenido principal

NUEVOS MECANISMOS DE DESREGULACION DE LA SEÑALIZACION POR CALCIO CONTRA EL GLIOBLASTOMA

RTI2018-094739-B-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2018
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE LLEIDA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 13
Encontrada(s) 1 página(s)

Repositori Obert UdL
Publicación Artículo científico (JournalArticle)

Tetralol derivative NNC-55-0396 targets hypoxic cells in the glioblastoma microenvironment: an organ-on-chip approach

  • Bayona, Clara
  • Alza, Lía
  • Ranđelović, Teodora
  • Sallán, Marta C.
  • Visa Pretel, Anna
  • Cantí Nicolás, Carles
  • Ochoa, Ignacio
  • Oliván, Sara
  • Herreros Danés, Judit
Glioblastoma (GBM) is a highly malignant brain tumour characterised by limited treatment options and poor prognosis. The tumour microenvironment, particularly the central hypoxic region of the tumour, is known to play a pivotal role in GBM progression. Cells within this region adapt to hypoxia by stabilising transcription factor HIF1-α, which promotes cell proliferation, dedifferentiation and chemoresistance. In this study we sought to examine the effects of NNC-55-0396, a tetralol compound which overactivates the unfolded protein response inducing apoptosis, using the organ-on-chip technology. We identified an increased sensitivity of the hypoxic core of the chip to NNC, which correlates with decreasing levels of HIF1-α in vitro. Moreover, NNC blocks the macroautophagic process that is unleashed by hypoxia as revealed by increased levels of autophagosomal constituent LC3-II and autophagy chaperone p62/SQSTM1. The specific effects of NNC in the hypoxic microenvironment unveil additional anti-cancer abilities of this compound and further support investigations on its use in combined therapies against GBM., This work was supported by the European Union’s Horizon 2020 research and innovation programme under grant agreement No 829010 (PRIME H2020-FETOPEN-2018-2019-2020-01). We also acknowledge the financial support from the Spanish Ministry of Economy and Competitiveness (MINECO fellowship, DIN 2020-011544); Ministry of Science and Innovation, the European Regional Development Fund (Proyect PID2021-126051OB-C41 funded by MCIN/AEI/10.13039/501100011033/FEDER, UE); MINECO Retos Program RTI2018-094739-B-I00 to CC and JH) and Fundació La Marató de TV3 (201909-30 to CC). CB would like to thank the Government of Aragon (DGA) for the predoctoral funding. AV is funded by Asociación Española Contra el Cáncer and LA is a recipient of an FI-AGAUR fellowship. We are grateful to Maria Casals and David Argilés for technical assistance. Cell culture experiments were performed in the Cell Culture Technical Scientific Service, Universitat de Lleida (Lleida, Catalonia, Spain). Authors would like to acknowledge the use of Servicio General de Apoyo a la Investigación-SAI, Universidad de Zaragoza.
Repositori Obert UdL
Publicación Artículo científico (JournalArticle)

Antitumor Effects of Ral-GTPases Downregulation in Glioblastoma.

  • Cemeli, Tània
  • Guasch Vallés, Marta
  • Ribes Santolaria, Marina
  • Ibars Estiarte, Eva Irene
  • Navaridas Fernández de Bobadilla, Raúl
  • Dolcet Roca, Xavier
  • Pedraza González, Neus
  • Colomina i Gabarrella, Neus
  • Torres Rosell, Jordi
  • Ferrezuelo, Francisco
  • Herreros Danés, Judit
  • Garí Marsol, Eloi
Glioblastoma (GBM) is the most common tumor in the central nervous system in adults. This neoplasia shows a high capacity of growth and spreading to the surrounding brain tissue, hindering its complete surgical resection. Therefore, the finding of new antitumor therapies for GBM treatment is a priority. We have previously described that cyclin D1-CDK4 promotes GBM dissemination through the activation of the small GTPases RalA and RalB. In this paper, we show that RalB GTPase is upregulated in primary GBM cells. We found that the downregulation of Ral GTPases, mainly RalB, prevents the proliferation of primary GBM cells and triggers a senescence-like response. Moreover, downregulation of RalA and RalB reduces the viability of GBM cells growing as tumorspheres, suggesting a possible role of these GTPases in the survival of GBM stem cells. By using mouse subcutaneous xenografts, we have corroborated the role of RalB in GBM growth in vivo. Finally, we have observed that the knockdown of RalB also inhibits cell growth in temozolomide-resistant GBM cells. Overall, our work shows that GBM cells are especially sensitive to Ral-GTPase availability. Therefore, we propose that the inactivation of Ral-GTPases may be a reliable therapeutic approach to prevent GBM progression and recurrence., This work was funded by the Catalan Government—AGAUR (2017 SGR-569), Ministerio de Ciencia e Innovaciön (PID2019-104859GB-I00; RTI2018-094739-B-I00; PID2019-104734RB-I00), and by the Xarxa de Bancs de Tumors de Catalunya sponsored by Pla Director d’Oncologia de Catalunya (XBTC). T Cemeli (FPU13/06590), M.Guasch (FPU17/00229), R. Navaridas (FPU18/04480), and M. Ribes (TALENT-IRBLleida) were supported by a pre-doctoral fellowship from Ministerio de Educación, Cultura y Deportes, and from Diputació de Lleida.
Repositori Obert UdL
Publicación Artículo científico (JournalArticle)

FAK inhibition induces glioblastoma cell senescence-like state through p62 and p27

  • Alza, Lía
  • Nàger Grifo, Mireia
  • Visa Pretel, Anna
  • Cantí Nicolás, Carles
  • Herreros Danés, Judit
Focal adhesion kinase (FAK) is a central component of focal adhesions that regulate cancer cell proliferation and migration. Here, we studied the effects of FAK inhibition in glioblastoma (GBM), a fast growing brain tumor that has a poor prognosis. Treating GBM cells with the FAK inhibitor PF-573228 induced a proliferative arrest and increased cell size. PF-573228 also reduced the growth of GBM neurospheres. These effects were associated with increased p27/CDKN1B levels and β-galactosidase activity, compatible with acquisition of senescence. Interestingly, FAK inhibition repressed the expression of the autophagy cargo receptor p62/SQSTM-1. Moreover, depleting p62 in GBM cells also induced a senescent-like phenotype through transcriptional upregulation of p27. Our results indicate that FAK inhibition arrests GBM cell proliferation, resulting in cell senescence, and pinpoint p62 as being key to this process. These findings highlight the possible therapeutic value of targeting FAK in GBM., This research was funded by Spanish Ministry of Science & Innovation (“Retos” Program), grant number RTI2018-094739-B-I00 to JH and CC. The APC was funded by Spanish Ministry of Science & Innovation
Repositori Obert UdL
Publicación Artículo científico (JournalArticle)

Targeting T-type channels in cancer: what is on and what is off?

  • Visa Pretel, Anna
  • Alza, Lía
  • Casas Benito, Adrian
  • Herreros Danés, Judit
  • Cantí Nicolás, Carles
Over the last 20 years several studies have demonstrated a pivotal role of T‐type calcium channels (TTCCs) in tumor progression. Cytotoxic effects of TTCC pharmacological blockers have been reported in vitro and in preclinical models. However, the roles of TTCCs in cancer physiology are only beginning to be understood. We discuss current evidence for the signaling pathways and cellular processes stemming from TTCC activity, mainly inferred by inverse reasoning from pharmacological block and, only a few, by gene silencing or channel activation. A thorough analysis indicates that drug‐induced cytotoxicity is partially an off‐target effect. Dissection of on/off‐target activity is paramount in order to elucidate TTCC physiological roles, and to deliver efficacious therapies suited to different cancer types and stages., This work was funded by the Spanish Ministry of Science and Innovation/FEDER “Una manera de hacer Europa” (“Retos” Program, grant RTI2018‐094739‐BI00 to JH and CC) and Fundació La Marató de TV3 (grant 201909 to C.C.). LA held a predoctoral FI AGAUR fellowship and AV was funded from Fundació La Marató de TV3.
Repositori Obert UdL
Publicación Artículo científico (JournalArticle)

T-type channels in cancer cells: Driving in reverse

  • Alza, Lía
  • Visa Pretel, Anna
  • Herreros Danés, Judit
  • Cantí Nicolás, Carles
In the strongly polarized membranes of excitable cells, activation of T-type Ca2+ channels (TTCCs) by weak depolarizing stimuli allows the influx of Ca2+ which further amplifies membrane depolarization, thus 'recruiting' higher threshold voltage-gated channels to promote action potential firing. Nonetheless, TTCCs perform other functions in the plasma membrane of both excitable and non-excitable cells, in which they regulate a number of biochemical pathways relevant for cell cycle and cell fate. Furthermore, data obtained in the last 20 years have shown the involvement of TTCCs in tumor biology, designating them as promising chemotherapeutic targets. However, their activity in the steadily-depolarized membranes of cancer cells, in which most voltage-gated channels are in the inactivated (nonconducting) state, is counter-intuitive. Here we discuss that in cancer cells weak hyperpolarizing stimuli increase the fraction of open TTCCs which, in association with Ca2+-dependent K+ channels, may critically boost membrane hyperpolarization and driving force for Ca2+ entry through different voltage-independent Ca2+ channels. Available evidence also shows that TTCCs participate in positive feedback circuits with signaling effectors, which may warrant a switch-like activation of pro-proliferative and pro-survival pathways in spite of their low availability. Unravelling TTCC modus operandi in the context of non-excitable membranes may facilitate the development of novel anticancer approaches., This work was funded by grants from the Spanish Ministry of Science and Innovation/FEDER “Una manera de hacer Europa” (Retos Program, No. RTI2018-094739-B-I00 to JH & CC) and Fundacio La Marató de TV3 (No. 235/C/2019 to CC). LA is a recipient of an FI-AGAUR predoctoral fellowship. AV was funded by La Marató de TV3.
Repositori Obert UdL
Publicación Artículo científico (JournalArticle)

Tetralol derivative NNC-55-0396 induces glioblastoma cell death by activating IRE1α, JNK1 and calcium signaling

  • Visa Pretel, Anna
  • Alza, Lía
  • Cantí Nicolás, Carles
  • Herreros Danés, Judit
Mibefradil and NNC-55-0396, tetralol derivatives with a proven ability to block T-type calcium channels in excitable cells, reduce cancer cell viability in vitro, causing cell death. Furthermore, they reduce tumor growth in preclinical models of Glioblastoma multiforme (GBM), a brain tumor of poor prognosis. Here we found that GBM cells treated with cytotoxic concentrations of NNC-55-0396 paradoxically increased cytosolic calcium levels through the activation of inositol triphosphate receptors (IP3R) and ER stress. We used pharmacological inhibitors and gene silencing to dissect the cell death pathway stimulated by NNC-55-0396 in GBM cell lines and biopsy-derived cultures. Calcium chelation or IP3R inhibition prevented NNC-55-0396-mediated cytotoxicity, indicating that ER calcium efflux is the cause of cell death. Upstream of calcium mobilization, NNC-55-0396 activated the IRE1α arm of the Unfolded Protein Response (UPR) resulting in the nuclear translocation of pro-apoptotic CHOP. Consistent with these findings, silencing IRE1α or JNK1 rescued the cell death elicited by NNC-55-0396. Therefore, we demonstrate that activation of IRE1α and calcium signaling accounts for the cytotoxicity of NNC-55-0396 in GBM cells. The delineation of the signaling pathway that mediates the abrupt cell death triggered by this compound can help the development of new therapies for GBM., We are grateful to Dr. S. Shaikh for help with initial calcium experiments and to Dr. E. Vilaprinyó for statistical analysis. We acknowledge the technical support of D. Argilés and assistance from the personnel of the Cell Culture and the Flow Cytometry Services of IRBLleida/UdL. This work was funded by grants from the Spanish Ministry of Science and Innovation/FEDER “Una manera de hacer Europa” (Retos Program, number RTI2018-094739-B-I00 to JH & CC) and Fundació La Marató de TV3 (number 235/C/2019 to CC). AV was funded by UdL, IRBLleida-Diputació de Lleida and La Marató de TV3. LA is a recipient of an FI-AGAUR predoctoral fellowship. Work supported by IRBLleida Biobank (B.0000682) and Plataforma Biobancos PT17/0015/0027/
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Tetralol derivative NNC-55-0396 targets hypoxic cells in the glioblastoma microenvironment: an organ-on-chip approach

  • Bayona, Clara
  • Alza, Lía
  • Randelovic, Teodora
  • Sallán, Marta C.
  • Visa, Anna
  • Cantí, Carles
  • Ochoa, Ignacio
  • Oliván, Sara
  • Herreros, Judit
Glioblastoma (GBM) is a highly malignant brain tumour characterised by limited treatment options and poor prognosis. The tumour microenvironment, particularly the central hypoxic region of the tumour, is known to play a pivotal role in GBM progression. Cells within this region adapt to hypoxia by stabilising transcription factor HIF1-α, which promotes cell proliferation, dedifferentiation and chemoresistance. In this study we sought to examine the effects of NNC-55-0396, a tetralol compound which overactivates the unfolded protein response inducing apoptosis, using the organ-on-chip technology. We identified an increased sensitivity of the hypoxic core of the chip to NNC, which correlates with decreasing levels of HIF1-α in vitro. Moreover, NNC blocks the macroautophagic process that is unleashed by hypoxia as revealed by increased levels of autophagosomal constituent LC3-II and autophagy chaperone p62/SQSTM1. The specific effects of NNC in the hypoxic microenvironment unveil additional anti-cancer abilities of this compound and further support investigations on its use in combined therapies against GBM.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

FAK inhibition induces glioblastoma cell senescence-like state through p62 and p27

  • Alza, Lía
  • Nàger Grifo, Mireia
  • Visa Pretel, Anna
  • Cantí Nicolás, Carles
  • Herreros Danés, Judit
Focal adhesion kinase (FAK) is a central component of focal adhesions that regulate cancer cell proliferation and migration. Here, we studied the effects of FAK inhibition in glioblastoma (GBM), a fast growing brain tumor that has a poor prognosis. Treating GBM cells with the FAK inhibitor PF-573228 induced a proliferative arrest and increased cell size. PF-573228 also reduced the growth of GBM neurospheres. These effects were associated with increased p27/CDKN1B levels and β-galactosidase activity, compatible with acquisition of senescence. Interestingly, FAK inhibition repressed the expression of the autophagy cargo receptor p62/SQSTM-1. Moreover, depleting p62 in GBM cells also induced a senescent-like phenotype through transcriptional upregulation of p27. Our results indicate that FAK inhibition arrests GBM cell proliferation, resulting in cell senescence, and pinpoint p62 as being key to this process. These findings highlight the possible therapeutic value of targeting FAK in GBM., This research was funded by Spanish Ministry of Science & Innovation (“Retos” Program), grant number RTI2018-094739-B-I00 to JH and CC. The APC was funded by Spanish Ministry of Science & Innovation
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

T-type channels in cancer cells: Driving in reverse

  • Alza, Lía
  • Visa Pretel, Anna
  • Herreros Danés, Judit
  • Cantí Nicolás, Carles
In the strongly polarized membranes of excitable cells, activation of T-type Ca2+ channels (TTCCs) by weak depolarizing stimuli allows the influx of Ca2+ which further amplifies membrane depolarization, thus 'recruiting' higher threshold voltage-gated channels to promote action potential firing. Nonetheless, TTCCs perform other functions in the plasma membrane of both excitable and non-excitable cells, in which they regulate a number of biochemical pathways relevant for cell cycle and cell fate. Furthermore, data obtained in the last 20 years have shown the involvement of TTCCs in tumor biology, designating them as promising chemotherapeutic targets. However, their activity in the steadily-depolarized membranes of cancer cells, in which most voltage-gated channels are in the inactivated (nonconducting) state, is counter-intuitive. Here we discuss that in cancer cells weak hyperpolarizing stimuli increase the fraction of open TTCCs which, in association with Ca2+-dependent K+ channels, may critically boost membrane hyperpolarization and driving force for Ca2+ entry through different voltage-independent Ca2+ channels. Available evidence also shows that TTCCs participate in positive feedback circuits with signaling effectors, which may warrant a switch-like activation of pro-proliferative and pro-survival pathways in spite of their low availability. Unravelling TTCC modus operandi in the context of non-excitable membranes may facilitate the development of novel anticancer approaches., This work was funded by grants from the Spanish Ministry of Science and Innovation/FEDER “Una manera de hacer Europa” (Retos Program, No. RTI2018-094739-B-I00 to JH & CC) and Fundacio La Marató de TV3 (No. 235/C/2019 to CC). LA is a recipient of an FI-AGAUR predoctoral fellowship. AV was funded by La Marató de TV3.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Tetralol derivative NNC-55-0396 induces glioblastoma cell death by activating IRE1α, JNK1 and calcium signaling

  • Visa Pretel, Anna
  • Alza, Lía
  • Cantí Nicolás, Carles
  • Herreros Danés, Judit
Mibefradil and NNC-55-0396, tetralol derivatives with a proven ability to block T-type calcium channels in excitable cells, reduce cancer cell viability in vitro, causing cell death. Furthermore, they reduce tumor growth in preclinical models of Glioblastoma multiforme (GBM), a brain tumor of poor prognosis. Here we found that GBM cells treated with cytotoxic concentrations of NNC-55-0396 paradoxically increased cytosolic calcium levels through the activation of inositol triphosphate receptors (IP3R) and ER stress. We used pharmacological inhibitors and gene silencing to dissect the cell death pathway stimulated by NNC-55-0396 in GBM cell lines and biopsy-derived cultures. Calcium chelation or IP3R inhibition prevented NNC-55-0396-mediated cytotoxicity, indicating that ER calcium efflux is the cause of cell death. Upstream of calcium mobilization, NNC-55-0396 activated the IRE1α arm of the Unfolded Protein Response (UPR) resulting in the nuclear translocation of pro-apoptotic CHOP. Consistent with these findings, silencing IRE1α or JNK1 rescued the cell death elicited by NNC-55-0396. Therefore, we demonstrate that activation of IRE1α and calcium signaling accounts for the cytotoxicity of NNC-55-0396 in GBM cells. The delineation of the signaling pathway that mediates the abrupt cell death triggered by this compound can help the development of new therapies for GBM., We are grateful to Dr. S. Shaikh for help with initial calcium experiments and to Dr. E. Vilaprinyó for statistical analysis. We acknowledge the technical support of D. Argilés and assistance from the personnel of the Cell Culture and the Flow Cytometry Services of IRBLleida/UdL. This work was funded by grants from the Spanish Ministry of Science and Innovation/FEDER “Una manera de hacer Europa” (Retos Program, number RTI2018-094739-B-I00 to JH & CC) and Fundació La Marató de TV3 (number 235/C/2019 to CC). AV was funded by UdL, IRBLleida-Diputació de Lleida and La Marató de TV3. LA is a recipient of an FI-AGAUR predoctoral fellowship. Work supported by IRBLleida Biobank (B.0000682) and Plataforma Biobancos PT17/0015/0027/
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Tetralol derivative NNC-55-0396 targets hypoxic cells in the glioblastoma microenvironment: an organ-on-chip approach

  • Bayona, Clara
  • Alza, Lía
  • Ranđelović, Teodora
  • Sallán, Marta C.
  • Visa Pretel, Anna
  • Cantí Nicolás, Carles
  • Ochoa, Ignacio
  • Oliván, Sara
  • Herreros Danés, Judit
Glioblastoma (GBM) is a highly malignant brain tumour characterised by limited treatment options and poor prognosis. The tumour microenvironment, particularly the central hypoxic region of the tumour, is known to play a pivotal role in GBM progression. Cells within this region adapt to hypoxia by stabilising transcription factor HIF1-α, which promotes cell proliferation, dedifferentiation and chemoresistance. In this study we sought to examine the effects of NNC-55-0396, a tetralol compound which overactivates the unfolded protein response inducing apoptosis, using the organ-on-chip technology. We identified an increased sensitivity of the hypoxic core of the chip to NNC, which correlates with decreasing levels of HIF1-α in vitro. Moreover, NNC blocks the macroautophagic process that is unleashed by hypoxia as revealed by increased levels of autophagosomal constituent LC3-II and autophagy chaperone p62/SQSTM1. The specific effects of NNC in the hypoxic microenvironment unveil additional anti-cancer abilities of this compound and further support investigations on its use in combined therapies against GBM., This work was supported by the European Union’s Horizon 2020 research and innovation programme under grant agreement No 829010 (PRIME H2020-FETOPEN-2018-2019-2020-01). We also acknowledge the financial support from the Spanish Ministry of Economy and Competitiveness (MINECO fellowship, DIN 2020-011544); Ministry of Science and Innovation, the European Regional Development Fund (Proyect PID2021-126051OB-C41 funded by MCIN/AEI/10.13039/501100011033/FEDER, UE); MINECO Retos Program RTI2018-094739-B-I00 to CC and JH) and Fundació La Marató de TV3 (201909-30 to CC). CB would like to thank the Government of Aragon (DGA) for the predoctoral funding. AV is funded by Asociación Española Contra el Cáncer and LA is a recipient of an FI-AGAUR fellowship. We are grateful to Maria Casals and David Argilés for technical assistance. Cell culture experiments were performed in the Cell Culture Technical Scientific Service, Universitat de Lleida (Lleida, Catalonia, Spain). Authors would like to acknowledge the use of Servicio General de Apoyo a la Investigación-SAI, Universidad de Zaragoza.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Targeting T-type channels in cancer: what is on and what is off?

  • Visa Pretel, Anna
  • Alza, Lía
  • Casas Benito, Adrian
  • Herreros Danés, Judit
  • Cantí Nicolás, Carles
Over the last 20 years several studies have demonstrated a pivotal role of T‐type calcium channels (TTCCs) in tumor progression. Cytotoxic effects of TTCC pharmacological blockers have been reported in vitro and in preclinical models. However, the roles of TTCCs in cancer physiology are only beginning to be understood. We discuss current evidence for the signaling pathways and cellular processes stemming from TTCC activity, mainly inferred by inverse reasoning from pharmacological block and, only a few, by gene silencing or channel activation. A thorough analysis indicates that drug‐induced cytotoxicity is partially an off‐target effect. Dissection of on/off‐target activity is paramount in order to elucidate TTCC physiological roles, and to deliver efficacious therapies suited to different cancer types and stages., This work was funded by the Spanish Ministry of Science and Innovation/FEDER “Una manera de hacer Europa” (“Retos” Program, grant RTI2018‐094739‐BI00 to JH and CC) and Fundació La Marató de TV3 (grant 201909 to C.C.). LA held a predoctoral FI AGAUR fellowship and AV was funded from Fundació La Marató de TV3.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Antitumor Effects of Ral-GTPases Downregulation in Glioblastoma.

  • Cemeli, Tània
  • Guasch Vallés, Marta
  • Ribes Santolaria, Marina
  • Ibars Estiarte, Eva Irene
  • Navaridas Fernández de Bobadilla, Raúl
  • Dolcet Roca, Xavier
  • Pedraza González, Neus
  • Colomina i Gabarrella, Neus
  • Torres Rosell, Jordi
  • Ferrezuelo, Francisco
  • Herreros Danés, Judit
  • Garí Marsol, Eloi
Glioblastoma (GBM) is the most common tumor in the central nervous system in adults. This neoplasia shows a high capacity of growth and spreading to the surrounding brain tissue, hindering its complete surgical resection. Therefore, the finding of new antitumor therapies for GBM treatment is a priority. We have previously described that cyclin D1-CDK4 promotes GBM dissemination through the activation of the small GTPases RalA and RalB. In this paper, we show that RalB GTPase is upregulated in primary GBM cells. We found that the downregulation of Ral GTPases, mainly RalB, prevents the proliferation of primary GBM cells and triggers a senescence-like response. Moreover, downregulation of RalA and RalB reduces the viability of GBM cells growing as tumorspheres, suggesting a possible role of these GTPases in the survival of GBM stem cells. By using mouse subcutaneous xenografts, we have corroborated the role of RalB in GBM growth in vivo. Finally, we have observed that the knockdown of RalB also inhibits cell growth in temozolomide-resistant GBM cells. Overall, our work shows that GBM cells are especially sensitive to Ral-GTPase availability. Therefore, we propose that the inactivation of Ral-GTPases may be a reliable therapeutic approach to prevent GBM progression and recurrence., This work was funded by the Catalan Government—AGAUR (2017 SGR-569), Ministerio de Ciencia e Innovaciön (PID2019-104859GB-I00; RTI2018-094739-B-I00; PID2019-104734RB-I00), and by the Xarxa de Bancs de Tumors de Catalunya sponsored by Pla Director d’Oncologia de Catalunya (XBTC). T Cemeli (FPU13/06590), M.Guasch (FPU17/00229), R. Navaridas (FPU18/04480), and M. Ribes (TALENT-IRBLleida) were supported by a pre-doctoral fellowship from Ministerio de Educación, Cultura y Deportes, and from Diputació de Lleida.